 "Lupin shares fall 2% on product recall in US")
Shares of drug firm Lupin fell over 2% today after the company recalled more than 54,000 vials of anti-bacterial injection Ceftriaxone manufactured at its Mandideep facility in Madhya Pradesh due to violation of current good manufacturing norms.
After a weak opening, the stock slipped further to trade 2.27% lower at Rs 1,398 on BSE.
On NSE, it went down by 2.33% to Rs 1,397.40.
The ongoing voluntary recall is a class-III recall and is for the US and Puerto Rico, according to the latest enforcement report on the US Food and Drug Administration (US FDA) site.
The recall is being initiated by the company's US arm Lupin Pharmaceuticals Inc covering 54,472 vials of Ceftriaxone injection in various strengths, it added.
Citing reasons for the recall, the US FDA said "finished products manufactured (at Lupin Ltd's Mandideep plant were) using active pharmaceutical ingredients whose intermediates failed specifications".
The injection is used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%